Overview Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease Status: Completed Trial end date: 2014-08-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease. Phase: Phase 3 Details Lead Sponsor: ISU Abxis Co., Ltd.